BioSpace News Archive

KP1237, a CD38-Targeting Antibody Recruiting Molecule (ARM™), to Be Tested in Combination with NK Cells to Treat Post-Transplant Multiple Myeloma Patients

Immunomedics, Inc.(NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that Dr. Behzad Aghazadeh, executive chairman, is scheduled to participate in a fireside chat at the Guggenheim Healthcare Talks | Oncology Day on Thursday, February 13, 2020 at 2:00 p.m. Eastern Time.

Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit in patients from the ICONIC trial

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that it will host a conference call and live webcast at 8:30 a.m. EST on Thursday, February 13, 2020 to report its fourth quarter and full year 2019 financial results and discuss business highlights.

Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Idea Forum | Oncology Day in New York City on Thursday, February 13, 2020 at 10 a.m. Eastern.

Digirad Corporation announced new financing to fund the growth strategy for its Building & Construction division for 2020.

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, announced that it has been notified by The Nasdaq Stock Market LLC that the Company has regained compliance with the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today announced that Patrick J. McEnany, Chief Executive Officer, and Steven Miller, Ph.D., Chief Operating Officer and Chief Scientific Officer, will be presenting at the 22nd Annual BIO CEO & Investor Conference, which is being held on February 10-11, 2020 at the New York Marriott Marquis Hotel in New York City.

Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will participate in fireside chats and host investor meetings at the following two conferences.

Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX) (“Foamix” or the “Company”), a specialty pharmaceutical company, announced today the publication of the Company’s Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the Journal of the American Academy of Dermatology (JAAD)